Establishment and validation of a novel anoikis-related prognostic signature of clear cell renal cell carcinoma

Front Immunol. 2023 Mar 28:14:1171883. doi: 10.3389/fimmu.2023.1171883. eCollection 2023.

Abstract

Background: Despite progression in its treatment, the clinical outcome of patients with clear cell renal cell carcinoma (ccRCC) remains not ideal. Anoikis is a unique form of programmed apoptosis, owing to insufficient cell-matrix interactions. Anoikis plays a crucial role in tumor migration and invasion, and tumor cells could protect themselves through the capacity of anoikis resistance.

Methods: Anoikis-related genes (ARGs) were obtained from Genecards and Harmonizome portals. The ARGs related to ccRCC prognosis were identified through univariate Cox regression analysis, then we utilized these ARGs to construct a novel prognostic model for ccRCC patients. Moreover, we explored the expression profile of ARGs in ccRCC using the Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) database. We also conducted Real-Time Polymerase Chain Reaction (RT-PCR) to probe ARGs expression of the risk score. Finally, we performed correlation analysis between ARGs and tumor immune microenvironment.

Results: We identified 17 ARGs associated with ccRCC survival, from which 7 genes were chosen to construct a prognostic model. The prognostic model was verified as an independent prognostic indicator. The expression of most ARGs was higher in ccRCC samples. These ARGs were closely correlated with immune cell infiltration and immune checkpoint members, and had independent prognostic value respectively. Functional enrichment analysis demonstrated that these ARGs were significantly associated with multiple types of malignances.

Conclusion: The prognostic signature was identified to be highly efficient in predicting ccRCC prognosis, and these ARGs were closely related to tumor microenvironment.

Keywords: anoikis; bioinformatics; clear cell renal cell carcinoma; prognostic model; tumor microenvironment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anoikis / genetics
  • Carcinoma*
  • Carcinoma, Renal Cell* / genetics
  • Humans
  • Kidney Neoplasms* / genetics
  • Prognosis
  • Tumor Microenvironment / genetics

Grants and funding

This work was supported by the National Natural Science Foundation of China (No.81803044, 81972373), the Natural Science Foundation of Fujian Province of China (No.2019J01016), and the funding of Science and Technology Planned Project of Medical and Health of Xiamen City (No.3502Z20194038).